Preserving Fertility During TRT: Evidence-Based Options for Men

Preserving Fertility During Testosterone Therapy: Clinical Insights and Evidence-Based Strategies

Testosterone Replacement Therapy (TRT) can be transformative for men experiencing hypogonadism or age-related hormonal decline. It restores energy, mood, libido, and focus. Yet, one essential concern often overlooked is fertility preservation.

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing luteinising hormone (LH) and follicle-stimulating hormone (FSH)—the two hormones vital for testicular function and sperm production. Without intervention, long-term TRT can lead to testicular shrinkage and even infertility.

At Levitas Academy, our R&D programme focuses on testosterone restoration without reproductive compromise, integrating clinical precision with evidence-based fertility support.

The Physiology: Why hCG Alone Is Insufficient

Spermatogenesis relies on a delicate interplay between LH and FSH:

LH – stimulates Leydig cells to produce testosterone within the testes.
FSH – activates Sertoli cells to support sperm maturation.

While human chorionic gonadotropin (hCG) mimics LH and sustains intratesticular testosterone, it cannot fully replace FSH’s role. Research from the University of Münster demonstrated that hCG alone maintains hormonal function but fails to sustain sperm output long term.

Men who initially regained spermatogenesis with combined hCG + hMG therapy saw rapid declines once FSH support was withdrawn:

After 6 months, sperm counts dropped to around 30% of their previous levels.
At 12 months, only 40% remained.
By 24 months, suppression persisted, with some cases of azoospermia.

The evidence is clear: hCG maintains testosterone, but FSH drives sustained sperm production.

Clinical Observations from the Levitas TRT Programme

Within the Levitas Hormones for Life network, men typically fall into two fertility profiles:

High baseline sperm count (75–100 million/mL) – may tolerate moderate hormonal suppression without significant fertility loss.
Low or borderline sperm count – require combined gonadotropin therapy (hCG + FSH/hMG) to preserve sperm production.

Each Levitas patient undergoes baseline semen analysis followed by repeat testing every 12–16 weeks, ensuring a personalised and responsive clinical pathway.

Advanced Fertility-Preserving Protocols

1. TRT + hCG (Baseline Preservation)

Goal: Maintain testicular function and partial spermatogenesis.

Testosterone (100–150 mg/week or equivalent topical/oral)
hCG (500–1,000 IU subcutaneously, 2–3× weekly)

2. TRT + hCG + FSH/hMG (Full Fertility Maintenance)

Goal: Sustain or restore full spermatogenesis.

hCG (1,000 IU subcutaneously, 2–3× weekly)
hMG (75 IU FSH + 75 IU LH) or recombinant FSH (75 IU, 2–3× weekly)

3. Enclomiphene-Based Protocol (Pituitary Preservation)

Goal: Preserve the body’s natural LH and FSH secretion.

Enclomiphene citrate (12.5–25 mg daily, 5 days/week)
Optional low-dose topical testosterone for symptomatic relief

Monitoring and Ongoing Evaluation

Parameter	Baseline	8–12 Weeks	24 Weeks	Target
Testosterone	✓	✓	✓	20–30 nmol/L
LH & FSH	✓	✓	✓	Mid-range
Estradiol	✓	✓	✓	<150 pmol/L
Semen Analysis	✓	✓	✓	Sustained sperm output

Adjunctive and Lifestyle Support

Optimising fertility outcomes extends beyond pharmacology.

Micronutrients: Zinc, selenium, vitamin D, and CoQ10.
Lifestyle factors: Sleep optimisation, stress reduction, reduced heat exposure, avoiding alcohol and steroids.
Aromatase management: Micro-dosed aromatase inhibitors when estradiol rises excessively.

The Levitas Approach

Levitas Clinics in London, Guildford, Esher, and Surrey lead the field in precision TRT—combining hormonal expertise with functional and regenerative medicine. Each programme is tailored to restore testosterone levels, vitality, and fertility simultaneously.

The Levitas Academy R&D division pioneers fertility-conscious protocols, integrating enclomiphene-based pituitary restoration, gonadotropin support, and micronutrient optimisation.

Key Takeaways

hCG alone preserves testosterone but not full fertility.
FSH and hMG are essential for sustained sperm production.
Enclomiphene protocols maintain pituitary function and natural balance.
Levitas Clinics specialise in fertility-preserving TRT.

✨ Explore personalised TRT and fertility management at Levitas Hormones for Life.

Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing

R&D

14 January 20262 min read

Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing

Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing Summary: Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing Overview Methylene blue (MB) and red light therapy enhance mitochondrial function and provide neuroprotection. Together, they synergistically improve cognitive and overall health. Mechanism of Action Methylene Blue Electron Donor: MB donates electrons in the mitochondrial electron transport chain (ETC), enhancing oxygen delivery and ATP production. Inhibition of Nitric Oxide Synthase: Reduces nitric oxide production, stabilizing blood pressure and improving blood flow. Red Light Therapy Photon Donor: Near-infrared light penetrates tissues, stimulating cytochrome c oxidase (Complex IV), enhancing ATP synthesis and cellular respiration. Benefits Energy Levels: Improved mitochondrial function increases ATP production, enhancing physical stamina and reducing fatigue. Cognitive Function: Supports brain health, improving memory, focus, and mental clarity. Mood Regulation: MB acts as a mild MAOI, balancing neurotransmitters and alleviating depression and anxiety. Pain Management: Anti-inflammatory and analgesic effects support conditions like arthritis and migraines. Infection Control: MB’s antimicrobial properties help prevent infections and support immune resilience. Dosage and Administration Methylene Blue: 1–2 mg/kg body weight. Monitoring required above 7 mg/kg. IV dose ~50 mg weekly. Oral dose ~80 mg and titrated upward. Red Light Therapy: Applied transcranially in the 660–1064 nm red–NIR spectrum for optimal penetration. Research and Evidence Protection against Neurodegeneration Gonzalez-Lima and Auchter (2015) showed MB + NIR light enhances mitochondrial respiration and protects neurons. From Mitochondrial Function to Neuroprotection Tucker et al. (2018) demonstrated MB supports mitochondrial repair and may assist in Alzheimer’s and Parkinson’s treatment. Infrared Phototherapy Henderson and Morries (2015) found that NIR light improves cell survival, memory, and glucose metabolism. Neurological & Psychological Applications Rojas & Gonzalez-Lima (2013) showed transcranial lasers enhance blood flow and ATP production in neurons. References Gonzalez-Lima & Auchter, 2015 – Frontiers in Cellular Neuroscience Tucker et al., 2018 – Molecular Neurobiology Henderson & Morries, 2015 – Neuropsychiatric Disease and Treatment Rojas & Gonzalez-Lima, 2013 – Biochemical Pharmacology Wadsworth & Korthuis, 2012 – American Journal of Physiology Hamblin, 2017 – AIMS Biophysics Sahl et al., 2016 – Investigative Ophthalmology & Visual Science Bennett et al., 2016 – Cochrane Reviews Greco et al., 2001 – Journal of Bioenergetics Cassano et al., 2015 – Psychiatry Journal

Read Article

Preserving Fertility During TRT: Evidence-Based Options for Men